39213-13-3

Basic information

• Product Name: 1-OXIDE-4-THIOMORPHOLINE
• Synonyms: 1-OXIDE-4-THIOMORPHOLINE;1-OXIDE-4-THIOMORPHOLINE HYDROCHLORIDE;4-THIOMORPHOLINE-1-OXIDE;1-OXIDE THIOMORPHOLINE HYDROCHLORIDE;ThioMorpholine, 1-oxide;4-Thiomorpholin-1-oxide;EOS-62359
• CAS NO: 39213-13-3
• Molecular Formula: C₄H₉NOS
• Molecular Weight: 119.19
• Mol File: 39213-13-3.mol

Chemical Properties

• Boiling Point: 318.322°C at 760 mmHg
• Flash Point: 146.316°C
• Appearance: /
• Density: 1.264g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.572
• CAS DataBase Reference: 1-OXIDE-4-THIOMORPHOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-OXIDE-4-THIOMORPHOLINE(39213-13-3)
• EPA Substance Registry System: 1-OXIDE-4-THIOMORPHOLINE(39213-13-3)

Safety Data

• Hazard Codes: Xi
• Statements: 36
• Safety Statements: 26
• Hazardous Substances Data: 39213-13-3(Hazardous Substances Data)

Usage

Structure

Contains both oxygen and sulfur in its structure, which contributes to its unique properties and reactivity.

Applications

a. Pharmaceutical industry used as an intermediate in the synthesis of other organic compounds.
b. Agrochemicals potential uses in the development of agricultural chemicals.
c. Organic chemistry reactions serves as a reagent in various organic chemistry reactions.

Chemical reactivity

Known for its ability to participate in a wide range of chemical reactions, making it a versatile compound.

Versatility

Capable of forming new chemical bonds, which allows it to be used as a building block in the synthesis of diverse organic compounds.

Industrial significance

1-OXIDE-4-THIOMORPHOLINE is a valuable compound with potential applications in different industrial sectors, including pharmaceuticals, agrochemicals, and organic chemistry.

InChI:InChI=1/C4H9NOS/c6-7-3-1-5-2-4-7/h5H,1-4H2

Upstream product

• 123-90-0 Thiomorpholin 
• 1115-15-7 divinyl sulfoxide 

Downstream Products

• 80348-41-0 N-(5,5-dimethyl-3-thioxo-2-cyclohexenyl)-perhydro-1,4-thiazine 1-oxide 
• 76176-88-0 N-Ac-1,4-thiazane-1-oxide 
• 1080062-06-1 4-{[6-(5-{1-[4-(cyclopropylsulfonyl)phenyl]-2-(tetrahydro-2H-pyran-4-yl)ethyl}-1H-pyrrol-2-yl)pyridin-3-yl]methyl}thiomorpholine 1-oxide 
• 1454648-68-0 (S)-3-[4-(1-oxo-1λ⁴-thiomorpholin-4-ylmethyl)-phenyl]-2,3-dihydro-[1,4]dioxino[2,3-b]pyridine 

Relevant articles and documents

Synthesis, Characterization and Catalytic Activity of a Tungsten(VI) Amino Triphenolate Complex

Abstract: Synthesis, characterization and catalytic activity of a novel tungsten(VI) amino triphenolate complex have been investigated. In particular, a tungsten(VI) amino triphenolate complex has been synthesized and tested in the oxidation of sulfides and cyclooctene, using hydrogen peroxide as terminal oxidant. The catalyst has proved to be air and water tolerant, also showing a good efficiency in terms of yields and selectivity. Moreover, an upgrade of our previous ligand synthesis is herein reported. The new developed procedure allows to obtain the triphenolamine in large scale without the use of chromatography for the intermediates purification. Graphical Abstract: [Figure not available: see fulltext.].

BENZODIOXANES FOR INHIBITING LEUKOTRIENE PRODUCTION

The present invention relates to compounds of formula (I) wherein R1 to R3, A, X and n are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorder. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

BENZODIOXANE INHIBITORS OF LEUKOTRIENE PRODUCTION FOR COMBINATION THERAPY

The present invention relates to a combination comprising compounds of formula (I): wherein R1 to R3, A, X and n are as defined herein, and an additional active agent. The present invention also relates to pharmaceutical compositions comprising these combinations, and methods of using these combinations to treat various diseases and disorders.

BENZOXAZEPINES AS INHIBITORS OF P13K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE

The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds. 9936396.1

Benzothiazole derivatives with activity as adenosine receptor ligands

The present invention relates to substituted benzothiazole derivitives and to their pharmaceutically acceptable salts useful for the treatment of diseases related to the adenosine receptor.

Use of thioamide oxazolidinones for the treatment of bone resorption and osteoporosis

The use of thioamide oxazolidinones for the treatment of bone resorption and osteoporosis is provided.

Oxazolidinone antibacterial agents having a thiocarbonyl functionality

The present invention provides compounds of Formula 1 or pharmaceutical acceptable salts thereof wherein A, G and R1are as defined in the claims which are antibacterial agents.

Oxazolidinone antibacterial agents having a thiocarbonyl functionality

The present invention provides compounds of Formula 1 or pharmaceutical acceptable salts thereof wherein A, G and R, are as defined in the claims which are antibacterial agents.

Thiomorpholine and morpholine oxidation by a cytochrome P450 in Mycobacterium aurum MO1. Evidence of the intermediates by in situ 1H NMR

Spectrophotometric assays of Mycobacterium aurum MO1 cells extracts gave evidence of a soluble cytochrome P450, involved in the degradative pathway of morpholine, a waste product from the chemical industry. In order to get further information, the kinetics of the biodegradation of the sulfur analogue thiomorpholine was monitored by using in situ nuclear magnetic resonance (NMR). This technique allowed the identification of two intermediates: the sulfoxide of thiomorpholine resulting from S-oxidation and thiodiglycolic acid owing to ring cleavage. The S-oxidation (S ← SO) represents one of the well-known reactions catalyzed by cytochromes P450. The inhibitory effect of metyrapone, a cytochrome P450 inhibitor, on the thiomorpholine and morpholine degradative abilities of M. aurum MO1 confirmed the involvement of a cytochrome P450. These results and the decrease of the rate of formation of the first intermediate during the morpholine degradation, 2-(2-aminoethoxy) acetate, proved the key role of the cytochrome P450 in the early events of the biodegradation, i.e, in the C - N bond cleavage.

Triazolo[1,5-c]pyrimidines and bronchodilation use thereof

1,2,4-Triazolo[1,5-c]pyrimidines substituted at the 7 position through a nitrogen atom which is part of a 1-oxo- or 1,1-dioxothiomorpholine ring have been found to have potent bronchodilator activity. Pharmacological methods of using these compounds and pharmaceutical compositions containing these compounds are also disclosed.